ENVAEnova International, Inc.

Next report: No date yet; none in the next 8 weeks
Last result: $4.15In line; vs $4.19 expected on Oct 22
Stock move on it: −6.62%; one session
Typical move: ±5.0%; average over 2 reports
Price: $167.01; −2.42% today · $6.10B cap

Past and upcoming reports


Oct 22, 2026	Sep 30, 2026	Time not given	$4.19	$4.15	In line−1.0%	−6.62%
Jul 21, 2026	Jun 30, 2026	Time not given	$3.97	Missed$2.95	Missed−25.7%	−3.45%2d

After the report

Jul 21, 2026 report

This covers the Jul 21, 2026 report. The Oct 22, 2026 numbers are in the table above.

EPS Misses by 20.9%, But Stock Surges 8.9%. Market Looks Past the Print

Enova reported Q2 EPS of $2.95, missing the $3.73 consensus by $0.78 (-20.9%). Despite the miss, shares rose 8.9% on heavy volume, suggesting investors focused on forward-looking growth prospects or internal guidance. The stock now trades at 17.6x TTM P/E, with consensus analyst target of $255.4. The lack of post-earnings news keeps the narrative ambiguous, but the price action is a clear signal of confidence in the company's trajectory.

Reported against expected

Missed

EPS of $2.95 missed consensus estimate of $3.73 by $0.78 (-20.9%), a significant miss.

Guidance

No explicit guidance was provided in the available data. The stock's positive reaction suggests the market may have received favorable implicit guidance or forward commentary.

How the stock reacted

Stock closed at $237.27 on 7/24, up 8.94% from previous close of $217.80, with volume of 858,568 shares (well above average).

What changed

EPS missed by 20.9%, yet stock surged 8.9%. market rewarded the outlook over the print.

What the price now assumes

The 8.9% rally indicates investors are pricing in sustained growth and ignoring the quarterly earnings miss.

What it means for the business

Upgrade bias: the bull case is intact if the miss was non-recurring. watch next quarter's revenue growth.

The next one to three months, as we saw it then

Better case40%

The EPS miss was due to temporary factors (e.g., higher provisions). Growth continues, and next quarter shows EPS beat.

Base case40%

Stock consolidates around current levels as investors await confirmation of the growth narrative. No major catalysts in near term.

Worse case20%

The miss signals deteriorating credit quality or operational issues. Analysts revise estimates lower, and multiple contracts.

If you hold it

Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.

If you are watching

Enter on a confirmed Q3 EPS beat and revenue acceleration. No-trade if the stock retraces below $200 without clear catalyst.

Scenario odds are a judgement, not measured.